RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastoma.
Siaw, J. T.; Claeys, A.; Lai, W.-Y.; Borenas, M.; Hilgert, E.; Bekaert, S.-L.; Sanders, E.; Kaya, I.; Van Dorpe, J.; Speleman, F.; Durinck, K.; Hallberg, B.; Palmer, R.; Van den Eynden, J.
Show abstract
High-risk neuroblastoma is characterized by MYCN amplification and high MYCN or MYC gene expression. These patients have a poor prognosis and there is an urgent need for more effective drugs. While strategies to develop inhibitors that directly target the MYC proteins have remained largely unsuccessful, recent preclinical studies have identified ATR, a key protein of the DNA damage response, as a promising alternative therapeutic target. Here we identified a strong RUVBL1 and RUVBL2 signature in transcriptomics data derived from different MYCN-driven mice tumors treated with ATR inhibitors. The RUVBL proteins form a complex with ATPase activity that has broad cellular functions and we demonstrate that pharmacological inhibition of this protein complex results in a strong reduction of MYC signaling, cell cycle arrest, DNA damage and apoptosis. We confirmed the association with MYCN and identified the RUVBL genes as independent prognosticators in human primary neuroblastoma data.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.